Owens & Minor (NYSE:OMI) Price Target Cut to $14.00 by Analysts at Barclays

Owens & Minor (NYSE:OMI) had its target price reduced by equities researchers at Barclays from $18.00 to $14.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price points to a potential upside of 16.67% from the stock’s current price.

Several other equities analysts have also issued reports on the stock. StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a report on Monday, August 26th. Citigroup upgraded Owens & Minor from a “neutral” rating to a “buy” rating and cut their price target for the company from $24.00 to $19.00 in a report on Friday, July 19th. Robert W. Baird decreased their price objective on Owens & Minor from $19.00 to $14.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, JPMorgan Chase & Co. cut their target price on Owens & Minor from $22.00 to $18.00 and set an “underweight” rating on the stock in a research note on Wednesday, August 21st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $18.71.

Owens & Minor Trading Down 10.2 %

OMI opened at $12.00 on Tuesday. The company has a quick ratio of 0.51, a current ratio of 1.09 and a debt-to-equity ratio of 2.17. The stock’s fifty day moving average is $14.62 and its two-hundred day moving average is $16.28. The company has a market capitalization of $925.20 million, a P/E ratio of -21.43, a PEG ratio of 0.43 and a beta of 0.41. Owens & Minor has a 52 week low of $11.75 and a 52 week high of $28.35.

Owens & Minor (NYSE:OMI) last released its quarterly earnings data on Monday, November 4th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.01. Owens & Minor had a positive return on equity of 14.66% and a negative net margin of 0.40%. The firm had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.68 billion. During the same period in the previous year, the company posted $0.44 earnings per share. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Analysts forecast that Owens & Minor will post 1.57 earnings per share for the current year.

Institutional Investors Weigh In On Owens & Minor

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Owens & Minor by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 8,749,866 shares of the company’s stock worth $242,459,000 after purchasing an additional 162,182 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of Owens & Minor by 30.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 6,371,440 shares of the company’s stock worth $86,014,000 after buying an additional 1,493,852 shares during the period. Gabelli Funds LLC grew its holdings in shares of Owens & Minor by 25.9% during the first quarter. Gabelli Funds LLC now owns 170,000 shares of the company’s stock valued at $4,711,000 after buying an additional 35,000 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Owens & Minor by 16.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,246,600 shares of the company’s stock valued at $16,829,000 after acquiring an additional 176,250 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Owens & Minor by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,534,204 shares of the company’s stock worth $61,213,000 after acquiring an additional 76,599 shares during the last quarter. Hedge funds and other institutional investors own 98.04% of the company’s stock.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.